Gary Owens, MD, president of Gary Owens Associates, discusses current treatments available for pulmonary arterial hypertension (PAH) and where future directions in research may lead.
In the future, we hope to see the development of disease-modifying agents for pulmonary arterial hypertension (PAH), said Gary Owens, MD, president of Gary Owens Associates.
Transcript:
What do you hope to see with regard to research on PAH within the next 5 years?
The good news is within the last, I would say, decade-plus, maybe 2 decades, we've really come a long way in understanding this disease. And our treatments really fall into just a handful of categories: endothelin receptor antagonists, PDE5 inhibitors, soluble guanylate cyclase stimulators, and prostacyclin therapies, whether that be administering prostacyclins, or administering receptor antagonists. And we now know that if you stratify patients according to risk, and those with moderate to high risk begin on either dual or triple therapy, the outcomes are better. So that's where are we are now.
But what can we think about in future directions? I think we'd like to see disease-modifying agents that really can maybe even reverse the course of the disease. Right now, what we can do is modify the progression of the disease. We're also understanding a lot more about the pathophysiology of this disease, and we're learning a lot about some new targets for treating this disease, so that becomes important. Targets that we're looking at, we're looking at vasointestinal polypeptide signaling, for instance. We're looking at PDGF signaling, for instance. We're looking at even estrogen signaling, and even the Nrf2 pathway that we're learning a lot about is something that we're learning more about. So I think there are lots of things that we're beginning to understand in this disease and looking at new directions.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Targeting MACC1 Offers Promising Therapeutic Strategy for PAH
April 10th 2024Positive responses seen following experiments involving metastasis-associated in colon cancer 1 (MACC1) indicate that the biomarker can be used to better diagnose and treat patients with pulmonary arterial hypertension (PAH).
Read More